Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App




Nuclear Medicine

Nuclear Medicine Enables Earlier COPD Diagnosis

In vivo ventilation/perfusion imaging can detect early lung alterations caused by cigarette smoke exposure and provides a noninvasive tool for evaluating lung dysfunction in preclinical studies. More...
09 Apr 2013

New Imaging Agent Provides Better Cancer Diagnosis with More Effective Staging

Researchers have shown that a new imaging dye is a successful agent in identifying and mapping tumors that have reached the lymph nodes. More...
08 Apr 2013

Surgery Bests Radiotherapy for Localized Prostate Cancer

Surgery offers superior survival benefit than radiotherapy for men with localized prostate cancer, according to a large observational study. More...
01 Apr 2013
Image:  T1- and T2-weighted MR images of focal lesions before and after systemic treatment (Photo courtesy of Dr. Jens Hillengass, German Cancer Research Center in Heidelberg, Germany).

Potential in MRI and PET-CT Lymphoma Cancer Characterization

Utilizing MRI in disease evaluation and PET-CT imaging in therapy response assessment could optimize patient outcome in lymphoma cancer. More...
01 Apr 2013

First Imaging Agent Approved for Visualization of Myocardial Sympathetic Innervation in Specific Heart Failure Patients

A new imaging agent has been approved in the United States for the scintigraphic evaluation of myocardial sympathetic innervation to help in the assessment of patients with NYHA class II or class III heart failure and LVEF ≤ 35%. More...
01 Apr 2013
Image: Multiparametric MRI for early treatment prediction of chemoradiation in oropharyngeal cancer: Upper row is pretreatment MRI of right base of tongue cancer (a = contrast enhanced T1 as anatomic correlate; b = native b1000 diffusion-weighted image; c = ADC-map; d = perfusion-map of IUAC). Middle row is two weeks during chemoradiation: same imaging sets, tumor volume will not help. No significant change in b1000, ADC nor perfusion-MRI indicate nonresponse and thus high risk of tumor relapse after end of treatment. Tumor relapse at PET-CT eight months after end of treatment, proven by histology (k) (Photo courtesy of Prof. Vincent Vandecaveye, University Hospital Leuven, Belgium).

Cutting-Edge Head and Neck Imaging Optimizes Healthcare in Clinical Practice

Radiation treatments have increased the need for cutting-edge imaging applications in the head and neck during pre- and post-treatment stages. More...
27 Mar 2013

Alzheimer’s Risk Gene Identified Using Connectome Scan

Scientists have discovered a new genetic risk factor for Alzheimer’s disease decades before the illness strikes. More...
20 Mar 2013
Silver Member
X-Ray QA Device
Accu-Gold+ Touch Pro
Multi-Use Ultrasound Table
Clinton
Portable X-ray Unit
AJEX140H
Medical Radiographic X-Ray Machine
TR30N HF


The Nuclear Medicine channel of MedImaging brings the latest in research and clinical radiotherapy, proton therapy, PET-CT, SPECT, SQUID, radiopharmacology, scintillography, trends and safety concerns.
Copyright © 2000-2026 Globetech Media. All rights reserved.